Long-Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease.
Pagan FL, Wilmarth B, Torres-Yaghi Y, Hebron ML, Mulki S, Ferrante D, Matar S, Ahn J, Moussa C.
Pagan FL, et al. Among authors: moussa c.
Mov Disord. 2021 Mar;36(3):740-749. doi: 10.1002/mds.28389. Epub 2020 Nov 20.
Mov Disord. 2021.
PMID: 33215762
Free PMC article.
Clinical Trial.